Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aew-541. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R known ✓ | P08069 | 19/20 | 1.00 |
| ▸ | INSR | P06213 | 7/20 | 1.00 |
| ▸ | LYN | P07948 | 5/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 4/20 | 1.00 |
| ▸ | SRC | P12931 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 1.00 |
| ▸ | STK4 | Q13043 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | ATR | Q13535 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936200 | 0.93 | IGF1R (0.97) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936204 | 0.93 | IGF1R (0.97) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936235 | 0.93 | IGF1R (0.97) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936382 | 0.91 | IGF1R (1.00) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936262 | 0.91 | IGF1R (1.00) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936264 | 0.91 | IGF1R (1.00) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936303 | 0.90 | IGF1R (0.98) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936322 | 0.90 | IGF1R (0.98) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL5936306 | 0.90 | IGF1R (0.98) | IGF1RINSRLYNROCK2SRC | |
| SCHEMBL1441421 | 0.89 | IGF1R (1.00) | IGF1RINSRLYNROCK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4721758-A1 | NOVEL MEDICINE FOR TREATING OSTEOSARCOMA | Japanese Foundation For Cancer Research (JP) | 2026-04-08 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4593956-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-08-06 | — | — | EP | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| CN-120051302-A | Methods for treating inactivity or chronic thyroid eye disease | 爱尔兰好利恩治疗有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2022-11-10 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115175701-A | Methods for treating thyroid eye disease | 爱尔兰霍里森治疗公司 | 2022-10-11 | — | — | CN | claimed |
| US-20220288025-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE | UNM RAINFOREST INNOVATIONS (US) | 2022-09-15 | — | — | US | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| CN-114761006-A | Methods of treating cancer resistant to kinase inhibitors | INSERM(法国国家健康医学研究院) | 2022-07-15 | — | — | CN | claimed |
| EP-4021500-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2022-07-06 | — | — | EP | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | IGF1R 101/4885INSR 447/4885LYN 1248/4885 |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | IGF1R 1329/4885INSR 2378/4885LYN 347/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | IGF1R 1324/4885INSR 598/4885LYN 4373/4885 |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | TPO, TSHR, TRHDE | IGF1R 916/4885INSR 1159/4885LYN 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.